

Clinical Trial Protocol

Iranian Registry of Clinical Trials

22 Jun 2026

Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI

Protocol summary

Study aim

Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI

Design

Interventional clinical trial with control and parallel groups, non-blind, randomized, phase 2 will performed on 288 patients. Randomization will performed using random number table.

Settings and conduct

The objective of this study is Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI in Kernan in 2022. Study population: Infertile women 18 to 40 years of age with unexplained infertility, mild male infertility, or due to polycystic ovary syndrome who have not responded to drug treatment alone and are candidates for intrauterine insemination. Study groups: Intervention and control groups. Sample size: 288 women. This is a randomized not blinded trial, in one center, in phase 2 study. Setting and conduct: Infertile women who are candidates for IUI after obtaining informed consent randomized into intervention and control groups.

Participants/Inclusion and exclusion criteria

Infertile women 18 to 40 years of age with unexplained infertility, mild male infertility, or due to polycystic ovary syndrome who have not responded to drug treatment alone and are candidates for intrauterine insemination.

Intervention groups

In the intervention group, after intrauterine insemination, 10 mg of oral dydrogesterone (Duphaston) is used three times a day to support the luteal phase. In the control group, progesterone suppository called vaginal cyclogest 400 micrograms is prescribed twice a day.

Main outcome variables

Chemical pregnancy, clinical pregnancy

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20151004024335N5**
Registration date: **2022-08-09, 1401/05/18**
Registration timing: **registered_while_recruiting**

Last update: **2022-08-09, 1401/05/18**

Update count: **0**

Registration date

2022-08-09, 1401/05/18

Registrant information

Name

robabe hoseinisadat

Name of organization / entity

infertility institute center of shahid sadughi

Country

Iran (Islamic Republic of)

Phone

+98 35 3824 7085

Email address

robabehoseini@ssu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-03-21, 1401/01/01

Expected recruitment end date

2023-03-21, 1402/01/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI

Public title

Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI in Kerman in 2022

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Infertile women with unexplained infertility Infertility with a mild male factor Infertility due to polycystic ovary syndrome who have not responded to drug treatment alone Age 18 to 40 years

Exclusion criteria:

Three times more history of unsuccessful intra uterine sperm insemination treatment azoospermia or Severe spermogram disorder Presence of endocrine diseases such as diabetes and severe thyroid disease

Age

From **18 years** old to **40 years** old

Gender

Female

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **288**

Randomization (investigator's opinion)

Randomized

Randomization description

Randomization was simple, individual, not blinded, using a random number table.

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Kerman University of Medical Sciences

Street address

Ibn Sina Street, Jihad Boulevard, Somayeh Road (Tahmasebabad)

City

kerman

Province

Kerman

Postal code

7619813159

Approval date

2022-07-19, 1401/04/28

Ethics committee reference number

IR.KMU.AH.REC.1401.072

Health conditions studied

1

Description of health condition studied

Infertility

ICD-10 code

N98.9

ICD-10 code description

Complication associated with artificial fertilization, unspecified

Primary outcomes

1

Description

Chemical pregnancy

Timepoint

14 days after embryo transfer

Method of measurement

Measurement of serum beta-HCG

Secondary outcomes

1

Description

Clinical pregnancy

Timepoint

Five weeks after embryo transfer

Method of measurement

Transvaginal ultrasound

2

Description

miscarriage rate

Timepoint

miscarriages before 20 weeks gestation

Method of measurement

Contact patients at the 20th week of pregnancy

Intervention groups

1

Description

Intervention group: Intervention group: To start the IUI cycle, women are given ovulation-stimulating drugs in the form of letrozole or clomiphene tablets for five days from the third day of the menstrual cycle. Then, from the eighth day, the gonadotropin cycle starts with a dose of 150-175 units. On the eleventh day of the menstrual cycle, transvaginal ultrasound is performed to monitor the follicle. Depending on the size of the follicle, the drug is continued and the ultrasound is repeated until one or

two follicles reach a size of 18 mm. If more than two follicles grow due to increased risk of multiple pregnancy or ovarian hyperstimulation, the cycle will be canceled. When the follicle size reaches 18 mm, 10,000 units of human chorionic gonadotropin (HCG) are used to stimulate ovulation. 36 hours after HCG injection, the partner's sperm is prepared by the infertility center laboratory and inseminated into the endometrial cavity with a sterile catheter by the infertility fellowship. Patients are then randomly divided into two groups. In the intervention group, which will consist of 144 women, oral diderogesterone tablets under the Dofaston brand are given as 10 mg three times a day and continue until the 11th week of pregnancy.

Category

Treatment - Drugs

2

Description

Control group: In the control group, after intrauterine insemination of sperm, a progesterone suppository called vaginal cyclogest 400 micrograms is administered twice a day.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Afzalipour Infertility Center

Full name of responsible person

Dr Robabe Hosseinisadat

Street address

Imam Khomeini Highway, Afzalipour Hospital

City

kerman

Province

Kerman

Postal code

۷۶۱۶۹۱۳۹۱۱

Phone

+98 34 3132 8486

Email

robabehosseinisadat@yahoo.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Kerman University of Medical Sciences

Full name of responsible person

Research Assistant, Kerman University of Medical Sciences

Street address

Ibn Sina Street, Jihad Boulevard, Somayeh Road (Tahmasebabad)

City

kermman

Province

Kerman

Postal code

7619813159

Phone

+98 34 3226 3815

Email

robabehosseinisadat@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Kerman University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Kerman University of Medical Sciences

Full name of responsible person

Robabe Hosseinisadat

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

infertility

Street address

Imam Khomeini Highway, Afzalipour Hospital

City

kerman

Province

Kerman

Postal code

7616913911

Phone

+98 34 3132 8486

Email

robabehosseinisadat@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity

Kerman University of Medical Sciences

Full name of responsible person

Robabe Hosseinisadat

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

infertility

Street address

Imam Khomeini Highway, Afzalipour Hospital

City

kerman

Province

Kerman

Postal code

۷۶۱۶۹۱۳۹۱۱

Phone

+98 34 3132 8486

Email

robabehosseinisadat@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity

Kerman University of Medical Sciences

Full name of responsible person

Robabe Hosseinisadat

Position

Assistant Professor

Latest degree

Subspecialist

Other areas of specialty/work

infertility

Street address

Imam Khomeini Highway, Afzalipour Hospital

City

kerman

Province

Kerman

Postal code

7616913911

Phone

+98 34 3132 8486

Email

robabehosseinisadat@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

The final result of the study will be published and there is no need to share individual participants' data

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available